Kidney Transplantation Clinical Trial
— DOVIREINOfficial title:
Medical Economic Evaluation and of Quality of Life of the Kidney Living Donors. Comparison of the Taking of Kidney by cœliosurgery (Pure or " Hand-assisted "), by cœliosurgery Assisted by Robot and by the Classic Technique of Open Donor Nephrectomy.
The main objective of this multicentre study is to conduct the evaluation of cost-efficiency
of various techniques of kidney taking with regard the quality of life of the kidney living
donors.
It will allow to compare three techniques of taking (open donor nephrectomy, cœliosurgery
pure or " hand-assisted " and cœliosurgery assisted by robot) and to determine their
respective advantages in quality of life, then their medico-economic consequences in a
cost-efficiency approach from the point of view of the society.
The evaluation will concern the donor and the receiver followed three months after the
taking.
The open donor nephrectomy will be the technique of reference with which will be compared
the two others.
Status | Completed |
Enrollment | 268 |
Est. completion date | July 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - The receiver is registered on the ABM list; - The receiver is on dialysis or in preterminal renal insufficiency; - The donor is a member of the circle of acquaintances of the receiver. Exclusion Criteria: - Risk of difficulties of follow-up during 3 months following the transplant (ex: patient not living in France); - Refusal of participation of the donor. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
France | CHU Saint Jacques de Besançon | Besancon | |
France | CHU Côte de Nacre de CAEN | Caen | |
France | CHU Montpied de Clermont-Ferrand | Clermont-ferrand | |
France | CHU Henri Mondor | Creteil | |
France | CHU Hôpital Michallon de Grenoble | Grenoble | |
France | CHU Bicêtre | Le Kremlin Bicetre | |
France | Hôpital Claude Huriez | Lille | |
France | CHU Lyon Sud | Lyon | |
France | Hôpital Edouard Herriot de Lyon | Lyon | |
France | CHU Hôpital de la Conception | Marseille | |
France | CHU Lapeyronie | Montpellier | |
France | CHU Brabois | Nancy | |
France | CHU Hôtel Dieu | Nantes | |
France | CHU Pasteur | Nice | |
France | Hôpital Necker | Paris | |
France | Hôpital Pitié Salpêtrière | Paris | |
France | Hôpital Saint-Louis | Paris | |
France | Hôpital Tenon | Paris | |
France | Hôpital Charles Nicolle | Rouen | |
France | CHU Saint Etienne | Saint Etienne | |
France | CHU Hautepierre | Strasbourg | |
France | CMC Foch | Suresnes | |
France | Hôpital de Rangueil | Toulouse | |
France | CHU Bretonneau | Tours |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of life of the donor | Quality of life of the donor as measured by EUROQOL (score 0 to 1) and SF 36 self-administered questionnaires (score 0 to 100 in each of 8 dimensions , at D-1 (the day before nephrectomy), D4 (4 days after nephrectomy) and D90 (90 days after nephrectomy). biological values of the donor and the receiver |
D-1 (day before nephrectomy), D4 (4 days after nephrectomy) and D90 (90 days after nephrectomy) | No |
Secondary | Sociodemographic data | At D-1 (the day before nephrectomy), sociodemographic data are collected | D-1, the day before nephrectomy | No |
Secondary | Comfort, physical and mental investment of the surgeon measured by the Borg and the NASA-TLX scale | The Borg scale consists of 7 questions corresponding to the level of discomfort in 7 body segments of the surgeon with responses ranging from 0 (no discomfort) to 10 (very very strong discomfort). The surgeon is questioned every 30 minutes during the surgery. The NASA-TLX scale consists in 8 questions about physical and mental investment with responses ranging from 0 (low) to 100 (high). The surgeon completes this scale immediately at the end of the surgical procedure. | Day 0, the actual day of nephrectomy for each donor | No |
Secondary | Biological values of the donor and the receiver | Blood count and serum electrolyte levels are collected. biological values of the donor and the receiver | D-1 (day before nephrectomy), D2 (2 days after nephrectomy) D4 (4 days after nephrectomy) and D90 (90 days after nephrectomy) | No |
Secondary | Treatments administered to the donor | Treatments administered to the donor from D0 (the actual day of nephrectomy for each donor) to D90 (90 days after nephrectomy). | D0 (the actual day of nephrectomy for each donor), D2 (2 days after nephrectomy), D4 (4 days after nephrectomy) and D90 (90 days after nephrectomy) | No |
Secondary | Medical exams performed on the donor | Medical exams performed on the donor from D0 (the actual day of nephrectomy for each donor) to D90 (90 days after nephrectomy). | D-1 (day before nephrectomy), D2 (2 days after nephrectomy) D4 (4 days after nephrectomy) and D90 (90 days after nephrectomy) | No |
Secondary | Information on surgical technique employed to achieve nephrectomy and description of the graft. | Type of surgery (open donor nephrectomy, standard or hand-assisted laparoscopic donor nephrectomyor laparoscopic robotic-assisted nephrectomy), Duration of surgery and of ischemia and description of the graft. | Day 0, the actual day of nephrectomy for each donor | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A |